IP Library Granted Patent US 10,082,474
Granted Patent B2
US 10,082,474 · App. 15/227,292 · Granted Sep 25, 2018

Method for analysis using X-ray fluorescence

Inventors: Lori J. Peterson (Los Alamos, NM); Cameron A. Mortillaro (Phoenix, AZ); Benjamin P. Warner (Los Alamos, NM); Nathan H. Zahler (Ashland, MA); Pratima Bharti (Portage, MI); Chang-Tai Hsieh (Chestnut Hill, MA); Emilia A. Solomon (Los Alamos, NM)
Assignee: ICAGEN, INC.
G01N23/223A61B6/485G01N33/487G01N33/4833G01N2223/076G01N2223/0766G01N2223/612G01N2223/6126
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,082,474
App. No.
15/227,292
Granted
Sep 25, 2018
Kind
B2
Abstract

The present invention is a method to quantify biomarkers. The method uses an X-ray fluorescence spectrometer to perform an X-ray fluorescence analysis on the sample to obtain spectral features derived from the biomarker; and quantifying the X-ray fluorescence signal of the biomarker.

Claims (18)

1. A method for measuring a response to a therapy, comprising

providing a sample which has been exposed to a therapy and a sample which has not been exposed to a therapy, the samples each comprising a biomarker comprising one or more chemicals that are related to a physiological condition;

preparing the samples for X-ray analysis by exposing the samples to a solution;

using an X-ray fluorescence spectrometer to perform an X-ray fluorescence analysis on the samples to obtain spectral features derived from the biomarker; and

quantifying the X-ray fluorescence signal of the biomarker and comparing the signal of the sample which has been exposed to a therapy and a sample which has not been exposed to a therapy;

wherein the X-ray fluorescence spectrometer irradiates the sample with polychromatic X-rays.

2. The method of claim 1 , wherein the solution is selected from a pH buffer, a redox buffer, a preservative, a fixative, and a sterilizing solution.

3. The method of claim 1 , wherein the solution is free of at least one chemical element having an atomic number greater than eight, where the element is present in the sample.

4. The method of claim 1 , wherein the solution is free of at least one of the chemicals or functional groups selected from the group consisting of dimethylsulfoxide, thiols, sulfate anion, sulfonate anions, chloride anion, bromide anion, fluoride anion, iodide anion, perchlorate anion, phosphate anion, and phosphonate anions.

5. The method of claim 1 , wherein the solution comprises one or more chemicals selected from the group consisting of amine, imine, nitrate anion, nitrite anion, ammonium cation, acetate anion, carboxylate anion, conjugate bases of carboxylic acids, carbonate anion, formalin, formaldehyde, ethanol, 2-propanol, and iminium cation.

6. The method of claim 1 , wherein the samples are fractionated to provide sample fractions.

7. The method of claim 6 , wherein the fractionating is performed using a technique selected from centrifugation, mechanical separation, chemical separation, enzymatic separation, condensation, chromatographic methods, gel electrophoresis, isoelectric focusing, 2-dimensional electrophoresis, precipitation, density gradient fractionation and immobilization of analytes to solid formats.

8. The method of claim 7 , wherein the solid format is selected from beads, membranes, arrays, microarrays, spin plate, or well plates.

9. The method of claim 1 , wherein at least one sample is disposed on or in a sample holder, and the sample holder comprises at least one chemical element which is not present in the sample.

10. The method of claim 1 , wherein the samples are biological samples.

11. The method of claim 10 , wherein the biological samples are selected from tissue samples, biological fluids, biopsy samples, cells, dried biospecimens, fresh biospecimens, immortalized cell lines, membranes, plasma, primary cell cultures, and subcellular fractionates.

12. The method of claim 1 , wherein the fluorescence analysis comprises multiple X-ray fluorescence analyses.

13. The method of claim 12 , wherein the multiple fluorescence analyses are obtained by disposing one or more of the samples at two or more different angles relative to an excitation source.

Assignments (13)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2020
From: ICAGEN, INC.; ICAGEN CORP.; XRPRO SCIENCES, INC.; CALDERA DISCOVERY, INC.
To: ADJACENT ACQUISITION CO., LLC
Reel/Frame 054069/0211 →
CHANGE OF NAME Recorded Oct 15, 2020
From: ADJACENT ACQUISITION CO., LLC
To: ICAGEN, LLC
Reel/Frame 054088/0578 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 052304/0304 →
RELEASE OF SECURITY INTEREST Recorded Apr 3, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 052304/0712 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
Reel/Frame 047046/0311 →
TERMINATION Recorded Sep 11, 2018
From: GPB DEBT HOLDINGS II, LLC
To: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
Reel/Frame 047046/0214 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047016/0859 →
SECURITY AGREEMENT Recorded Sep 5, 2018
From: ICAGEN-T, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.; ICAGEN, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 047317/0860 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; ICAGEN-T, INC.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042378/0935 →
SECURITY INTEREST Recorded May 15, 2017
From: ICAGEN, INC.; ICAGEN CORP.; CALDERA DISCOVERY, INC.; XRPRO SCIENCES, INC.
To: GPB DEBT HOLDINGS II, LLC
Reel/Frame 042379/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2016
From: PETERSON, LORI J.; MORTILLARO, CAMARON A.; WARNER, BENJAMIN P.; ZAHLER, NATHAN H.; BHARTI, PRATIMA; HSIEH, CHANG-TAI; SOLOMON, EMILIA A.
To: CALDERA PHARMACEUTICALS, INC.
Reel/Frame 039421/0844 →
CHANGE OF NAME Recorded Aug 12, 2016
From: CALDERA PHARMACEUTICALS, INC.
To: XRPRO SCIENCES, INC.
Reel/Frame 039670/0704 →
CHANGE OF NAME Recorded Aug 12, 2016
From: XRPRO SCIENCES, INC.
To: ICAGEN, INC.
Reel/Frame 039670/0712 →
Continuity (4)
Continuation 14715206 · May 18, 2015
Continuation 13317341 · Oct 14, 2011
Provisional Application 61455030 · Oct 14, 2010
Related Publication 20160341678A1 · Nov 24, 2016